Closing BMRN (Biomarin) outperform
I got everything I could have asked for out of this pick, and I've seen the share price hit 40 and bounce back down a couple of times now. The most recent run-up seems to be on buyout rumors, but I'm going to bet against the rumors and try and exit at a high point. Strong revenues for Naglazyme, Aldurazyme, and Kuvan seem to be baked into the share price and there would seem to be more downside than upside. If it goes below 35 again I'll probably get back in.